Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity
Open Access
- 1 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Radiation Oncology
- Vol. 16 (1), 1-9
- https://doi.org/10.1186/s13014-021-01749-x
Abstract
Background: Radiation therapy and chemoradiation therapy play a major role in the definitive management of esophageal cancer. Survival in esophageal cancer patients is still relatively poor, mostly due to high rates of local recurrence and distant metastases. It is hypothesized that dose escalation in radiotherapy could improve outcomes. Therefore, this retrospective analysis aimed to investigate the outcomes and toxicity in patients treated with local dose escalation by means of using simultaneous integrated boost concepts. Methods: Between 2012 and 2018, 101 patients with esophageal carcinoma were analyzed in this monocentric, retrospective study. All patients received definitive chemoradiation or radiation therapy alone as intensity modulated radiotherapy. The prescribed dose was 50.4 Gy in 28 fractions to the primary tumor and the elective lymph nodes as well as a simultaneous integrated boost (SIB) with 58.8 Gy to macroscopic tumor and lymph node metastases. Endpoints were overall survival (OS), progression free survival (PFS), local control rate (LCR) and toxicity. Results: 60 patients (59.4%) received chemoradiation, 41 patients (40.6%) radiotherapy alone. The median follow up was 17 months (range 0–75 months). OS, PFS and LCR were at 63.9%, 53.9% and 59.9% after 1 year and 37.6%, 34.5% and 36.1%, respectively after 3 years. 16 patients (15.8%) in total developed a locoregional recurrence within the field of radiation. In 48 patients (47.5%) at least one grade III° (CTCAE) toxicity was documented during radiotherapy, mostly dysphagia (36 pat., 75%). One patient suffered from a grade IV° pneumonia. Conclusion: This retrospective analysis demonstrates that a SIB concept in definitive (chemo)radiation therapy is safe and feasible, showing acceptable outcomes in this patient cohort. Considering that this cohort mainly consists of elderly patients not eligible for chemotherapy in many cases, we emphasize the aspect of SIB radiation therapy as potential partial compensation for omitted simultaneous chemotherapy. Prospective studies are needed for validation.Keywords
Funding Information
- Projekt DEAL
This publication has 38 references indexed in Scilit:
- Experience with Oesophageal Cancer: A Ten-Year Single Centre Study Reflecting Daily PracticeISRN Gastroenterology, 2013
- High-dose definitive concomitant chemoradiotherapy in non-metastatic locally advanced esophageal cancer: toxicity and outcomeDiseases of the Esophagus, 2010
- Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagusEmergencias, 2010
- Phase III Trial of Protracted Compared With Split-Course Chemoradiation for Esophageal Carcinoma: Fédération Francophone de Cancérologie Digestive 9102Journal of Clinical Oncology, 2007
- Referral Patterns, Treatment Choices, and Outcomes in Locoregional Esophageal Cancer: A Population-Based Analysis of Elderly PatientsJournal of Clinical Oncology, 2007
- Chemoradiation Followed by Surgery Compared With Chemoradiation Alone in Squamous Cancer of the Esophagus: FFCD 9102Journal of Clinical Oncology, 2007
- Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagusPublished by Wiley ,2006
- Chemoradiation With and Without Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of the EsophagusJournal of Clinical Oncology, 2005
- Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment TrialsThe New England Journal of Medicine, 1999
- Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer of the EsophagusThe New England Journal of Medicine, 1992